Fig. 1

Lymphocyte profiling in liver tissues. A CD3 + , B CD4 + , C CD8 + , D CD20 + , E CD57 + , F PD-1 + and G PD-L1 + positive tissue areas, representing corresponding lymphocytes in liver biopsies from normal livers (n = 10), NASH (n = 10) or anti-PD-1-antibody-treated patients with hepatotoxic (IO-treated, pembrolizumab- or nivolumab-treated patients 1–5, corresponding to the patients listed in Table 1.) or without adverse events (IO-treated no AE) patients (n = 2). Individual values for each patient data points are shown, the transverse bars represent the mean value, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. normal livers, ˆ p < 0.05, ˆˆp < 0.01 ˆˆˆp < 0.001 vs. NASH, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. PBC. H PD-1 and I PD-L1 protein expression in samples: 1 – 2) PBMC cells from volunteers, 3 – 4) human MDA-MB-231 breast cancer cells, 5) murine J774 macrophage cells and 6) HIBEpiC cells. B-actin of the same blots are shown to demonstrate protein loading. (Uncropped blots are shown in Supplementary Fig. 1.) J HIBEpiC viability as a function of time in the presence of indicated concentrations of pembrolizumab (pembro, corresponding to ̴̴ 0.4, 4 or 40 pM), doxorubicin (doxo, corresponding to ̴̴ 10 µM) or vehicle (control). Data is expressed as mean ± S.D., (n = 5), and presented as fold-change vs. control, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle